TW427906B - Antifungal compositions - Google Patents

Antifungal compositions

Info

Publication number
TW427906B
TW427906B TW086104612A TW86104612A TW427906B TW 427906 B TW427906 B TW 427906B TW 086104612 A TW086104612 A TW 086104612A TW 86104612 A TW86104612 A TW 86104612A TW 427906 B TW427906 B TW 427906B
Authority
TW
Taiwan
Prior art keywords
pharmaceutically acceptable
effective
amount
antifungal compositions
pharmaceutically
Prior art date
Application number
TW086104612A
Other languages
English (en)
Inventor
Maneesh J Nerurkar
William A Hunke
Michael J Kaufman
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21772585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW427906(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of TW427906B publication Critical patent/TW427906B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW086104612A 1996-04-19 1997-04-10 Antifungal compositions TW427906B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1563896P 1996-04-19 1996-04-19

Publications (1)

Publication Number Publication Date
TW427906B true TW427906B (en) 2001-04-01

Family

ID=21772585

Family Applications (1)

Application Number Title Priority Date Filing Date
TW086104612A TW427906B (en) 1996-04-19 1997-04-10 Antifungal compositions

Country Status (4)

Country Link
US (2) US5952300A (zh)
KR (1) KR100330444B1 (zh)
TW (1) TW427906B (zh)
ZA (1) ZA973344B (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4936595B2 (ja) * 1999-03-03 2012-05-23 イーライ リリー アンド カンパニー ミセル形成界面活性剤を含有するエキノカンジン薬学的処方物
GB0409077D0 (en) * 2004-04-23 2004-05-26 Neutec Pharma Plc Treatment of fungal infections
US8017368B2 (en) * 2005-10-20 2011-09-13 University Of South Florida Molecular delivery to cells using aspirin-related compounds
BRPI0715113A2 (pt) * 2006-07-26 2013-06-04 Sandoz Ag Sandoz Sa Sandoz Ltd formulaÇço de caspofungina
AU2008269140A1 (en) 2007-06-26 2008-12-31 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
US20090075870A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched caspofungin
US8048853B2 (en) * 2008-06-13 2011-11-01 Xellia Pharmaceuticals Aps Process for preparing pharmaceutical compound and intermediates thereof
US20100256074A1 (en) * 2008-06-25 2010-10-07 Chaim Eidelman Processes for preparing high purity aza cyclohexapeptides
WO2009158034A1 (en) * 2008-06-25 2009-12-30 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Caspofungin free of caspofungin impurity a
NZ600118A (en) 2009-11-23 2014-08-29 Cubist Pharm Inc Lipopeptide compositions and related methods
ES2593727T3 (es) * 2010-09-20 2016-12-12 Xellia Pharmaceuticals Aps Composición de caspofungina
CN102746384B (zh) * 2011-04-22 2016-01-20 上海天伟生物制药有限公司 一种高纯度的卡泊芬净或其盐及其制备方法和用途
CN102488889B (zh) * 2011-09-26 2014-01-22 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
CN103315969B (zh) * 2011-09-26 2016-05-18 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
SI2922530T1 (sl) * 2012-11-20 2017-04-26 Fresenius Kabi Usa, Llc Formulacije kaspofugin acetata
WO2015052115A1 (en) 2013-10-07 2015-04-16 Galenicum Health S.L. Stable pharmaceutical formulations of caspofungin
US9675659B2 (en) 2015-08-21 2017-06-13 Trilogy Therapeutics, Inc. Methods of treating lung infection with caspofungin
WO2019157453A1 (en) 2018-02-12 2019-08-15 Trilogy Therapeutics, Inc. Caspofungin compositions for inhalation
BR112022015170A2 (pt) 2020-03-12 2022-10-11 Baxter Int Formulações de daptomicina contendo uma combinação de sorbitol e manitol

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US5120859A (en) * 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
US5378805A (en) * 1990-08-29 1995-01-03 United States Of America Immunoreactive HTLV-I/II ENV and POL peptides
US5336756A (en) * 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
US5466781A (en) * 1991-05-24 1995-11-14 Chiron Therapeutics Process for purifying bacterially produced M-CSF
US5378804A (en) * 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
US5552521A (en) * 1995-02-10 1996-09-03 Merck & Co., Inc. Process for preparing certain aza cyclohexapeptides
US5665760A (en) * 1995-09-18 1997-09-09 Sanofi Winthrop, Inc. Lyophilized thioxanthenone antitumor agents

Also Published As

Publication number Publication date
US5952300A (en) 1999-09-14
ZA973344B (en) 1997-10-20
KR20000005497A (ko) 2000-01-25
US6136783A (en) 2000-10-24
KR100330444B1 (ko) 2002-11-18

Similar Documents

Publication Publication Date Title
MY126305A (en) Antifungal compositions
TW427906B (en) Antifungal compositions
AU4264396A (en) Cosmetic or pharmaceutical compositions containing mangiferin or derivatives thereof
MX9701538A (es) Sales de un derivado del indol contra la migraña.
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
AU7535798A (en) Novel cyclosporin derivatives, preparation and pharmaceutical compositions containing same
IL114596A0 (en) Pharmaceutical compositions for administration by inhalation
BR9707064A (pt) Novos derivados 19-nor-pregneno
BG104434A (en) 2-halo-6-o-substituted ketolide derivatives
RS50046B (sr) Farmaceutske kompozicije tizoksanida i nitazoksanida
UA42733C2 (uk) Похідні біснафталіміду та їх фармацевтично прийнятні кислотно-адитивні солі, фармацевтична композиція з цитотоксичною активністю, яка їх містить
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
WO1999011651A3 (en) 3-descladinose 6-o-substituded erythromycin derivatives
AP9801235A0 (en) Erythromycin derivatives.
MY116837A (en) Compositions for inhibiting platelet aggregation
MY109729A (en) Benzofuranylimidazole derivatives, a process for the preparation and therapeutical compositions containing the same
MX9601852A (es) Formulaciones de estramustina con propiedades farmaceuticas mejoradas.
BG103985A (en) Multicyclic derivatives of erythromycin
NZ290236A (en) Inhibition ofleucotriene biosynthesis and pharmaceutical compositions comprising aryl-urea derivatives
ECSP972084A (es) Composiciones que comprenden un agente antifungoso y un tampon de acetato
ATE109981T1 (de) Therapeutische mittel.
JO1679B1 (en) A new, therapeutically active compound and method for preparing it
MY111630A (en) Amino acid derivatives.

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MK4A Expiration of patent term of an invention patent